Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression
New Pill Slows Advanced Prostate Cancer After Other Drugs Fail
A randomized phase III trial in 417 patients with metastatic castration-resistant prostate cancer after progression on or intolerance to abi…
A new daily pill slowed advanced prostate cancer progression by 42 percent in men whose disease grew despite standard hormone therapy and ch…
Apalutamide plus ADT shows favorable survival trends in Asian and Japanese mCSPC patients
Asian Men See Real Benefit From New Prostate Drug
A Bayesian post hoc analysis of a phase 3 trial in Asian (n=221) and Japanese (n=51) patients with metastatic castration-sensitive prostate …
New analysis confirms the drug works well for Asian and Japanese patients, helping men with advanced prostate cancer live longer and delay p…
Systematic review of 18 case reports characterizes apalutamide-induced severe cutaneous adverse reactions in prostate cancer
Study reviews rare but severe skin reactions to prostate cancer drug apalutamide
A systematic review of 18 global case reports in prostate cancer patients found apalutamide was associated with severe cutaneous adverse rea…
Severe skin reactions like Stevens-Johnson syndrome appeared in most cases of patients taking apalutamide for prostate cancer, starting abou…
PSMA PET parameters predict biochemical recurrence in high-risk prostate cancer after neoadjuvant hormonal therapy
PET scan measures may help predict prostate cancer recurrence after hormone therapy
A phase II RCT of 89 high-risk primary prostate cancer patients found that posttreatment PSMA-expressing volume and pretreatment metastatic …
A specialized PET scan after hormone therapy can predict which high-risk prostate cancer patients face a higher risk of their disease return…